The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

The drug, being developed for a rare genetic disorder and currently under review in the U.S., is seen by some investors as ...

Halozyme claims Merck infringed on patents in developing a subcutaneous form of Keytruda. Elsewhere, Vanda’s challenge to an ...

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...